Title: Filament Health Corp. Announces Non-Brokered Private Placement Unit Offering Led by Negev Capital
Summary: Filament Health Corp., a clinical-stage natural psychedelic drug development company, has announced its intention to complete a non-brokered private placement unit offering for gross proceeds of up to CAD 2,000,000. The offering will be led by Negev Capital, a leading venture fund in the psychedelic drug development space. The proceeds will be used to advance Filament’s Phase 2 methamphetamine use disorder clinical trial and for other general corporate purposes.
Headings:
1. Introduction
2. Filament Health Corp’s Private Placement Offering
2.1 Offering Details
2.2 Lead Investor
3. Use of Proceeds
4. Regulatory Approval and Hold Period
5. Legal Disclaimer
Subheadings:
– Filament Health Corp’s Plans for Private Placement Offering
– Offering Details and Lead Investor
– Intended Use of Proceeds
– Regulatory Approval and Hold Period
– Legal Disclaimer
